Cantor Fitzgerald Reiterates Overweight Rating on BioCryst Pharmaceuticals, Inc. (BCRX)

Market Context

BioCryst Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $10.02 with a market capitalization of $1.6B.

Analyst coverage from Cantor Fitzgerald provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for BioCryst Pharmaceuticals, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for BioCryst Pharmaceuticals, Inc.

Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jun 30, 2026	HC Wainwright & Co.	Buy	N/A
Jun 30, 2026	Cantor Fitzgerald	Overweight	N/A
May 07, 2026	Citizens	Market Outperform	N/A
May 07, 2026	Wedbush	Outperform	N/A
May 06, 2026	Needham	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View BCRX Stock Page